Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.63 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.63 |
| ▸ | KDR | P35968 | 2/20 | 0.56 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.54 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361209 | 1.00 | TGFBR1 (1.00) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL10000768 | 0.91 | TGFBR1 (0.83) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL31718274 | 0.91 | TGFBR1 (0.83) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL6762324 | 0.89 | TGFBR1 (0.80) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL6757465 | 0.85 | TGFBR1 (0.74) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL7250793 | 0.85 | TGFBR1 (0.74) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL6757519 | 0.85 | TGFBR1 (0.74) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL30938087 | 0.83 | TGFBR1 (0.71) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL6760983 | 0.83 | TGFBR1 (0.71) | TGFBR1MTORMAPK14RIPK2ACVR1B | |
| SCHEMBL29259779 | 0.83 | TGFBR1 (0.71) | TGFBR1MTORMAPK14RIPK2ACVR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1500 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122038274-A | Method for inducing differentiation and maturation of alveolar organoids and application thereof | 广州国家实验室 | 2026-05-15 | — | — | CN | claimed |
| CN-122038284-A | Method for inducing differentiation of anterior foregut endoderm cells to form lung progenitor cells and application thereof | 广州国家实验室 | 2026-05-15 | — | — | CN | claimed |
| CN-122038299-A | Induction medium for transdifferentiating cells into dopaminergic neuron source exosomes by using small molecular compound in vitro induction, culture method and application | 广西壮族自治区人民医院 | 2026-05-15 | — | — | CN | claimed |
| WO-2025251988-A9 | REAGENT COMBINATION OR KIT FOR CONSTRUCTING EMBRYOID AND USE THEREOF | 广州国家实验室 | 2026-05-15 | — | — | WO | claimed |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | TRAILHEAD BIOSYSTEMS INC (US) | 2026-05-07 | — | — | US | claimed |
| US-20260108496-A1 | METHODS FOR REPROGRAMING EXHAUSTED T CELLS AND BOOSTING IMMUNE CHECKPOINT BLOCKADE THERAPY FOR CANCER | OHIO STATE INNOVATION FOUNDATION (US) | 2026-04-23 | — | — | US | claimed |
| US-20260092257-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMATOPOIETIC PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2026-04-02 | — | — | US | claimed |
| US-12590297-B2 | Differentiation method | KONINKLIJKE NEDERLANDSE AKADEMIE VAN WETENSCHAPPEN (NL) | 2026-03-31 | — | — | US | claimed |
| EP-4714459-A1 | COMPOSITION FOR PREVENTING OR TREATING SALIVARY GLAND DISEASES, COMPRISING EPITHELIAL PROGENITOR CELLS OR STEM CELLS IN MINOR SALIVARY GLAND DUCT | UIF (University Industry Foundation), Yonsei University (KR) | 2026-03-25 | — | — | EP | claimed |
| EP-3690022-B1 | CELL CULTURE MEDIUM FOR CULTURING ORGANOID, CULTURE METHOD, AND ORGANOID | UNIV KEIO (JP) | 2026-03-18 | — | — | EP | claimed |
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad | 2016-06-30 | — | — | US | claimed |
| WO-2016029267-A1 | A METHOD FOR CULTURING MESENCHYMAL STEM CELLS | PRINCE HENRY'S INSTITUTE OF MEDICAL RESEARCH TRADING AS THE HUDSON INSTITUTE OF MEDICAL RESEARCH (AU) | 2016-03-03 | — | — | WO | claimed |
| WO-2015061568-A1 | REPROGRAMMING CARDIOMYOCYTES WITH ONE TRANSCRIPTION FACTOR | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-04-30 | — | — | WO | claimed |
| WO-2015038704-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-19 | — | — | WO | claimed |
| US-20140348889-A1 | Compositions and Methods for Treating and Preventing Neointimal Stenosis | YALE UNIVERSITY (US) | 2014-11-27 | — | — | US | claimed |
| US-8883502-B2 | Expandable cell source of neuronal stem cell populations and methods for obtaining and using them | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-11 | — | — | US | claimed |
| US-20130236436-A1 | EXPANDABLE CELL SOURCE OF NEURONAL STEM CELL POPULATIONS AND METHODS FOR OBTAINING AND USNIG THEM | ZHANG KANG (US) | 2013-09-12 | — | — | US | claimed |
| US-20130071931-A1 | PROCESS FOR HEPATIC DIFFERENTIATION FROM INDUCED HEPATIC STEM CELLS, AND INDUCED HEPATIC PROGENITOR CELLS DIFFERENTIATED THEREBY | NATIONAL CANCER CENTER (JP) | 2013-03-21 | — | — | US | claimed |
| WO-2012167261-A2 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING NEOINTIMAL STENOSIS | YALE UNIVERSITY (US) | 2012-12-06 | — | — | WO | claimed |
| US-20040220230-A1 | Pyridinylimidazoles | SMITHKLINE BEECHAM P.L.C. | 2004-11-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260108496-A1 | METHODS FOR REPROGRAMING EXHAUSTED T CELLS AND BOOSTING IMMUNE CHECKPOINT BLOCKADE THERAPY FOR CANCER | BMP4, CD274, WNT3A | TGFBR1 5/4885MTOR 498/4885MAPK14 1797/4885 |
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | MYLK2, TNNI3, TNNT2 | TGFBR1 3113/4885MTOR 934/4885MAPK14 1708/4885 |
| US-20260092257-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEMATOPOIETIC PROGENITOR CELLS | FLT4, CSF3R, FGFR3 | TGFBR1 712/4885MTOR 2623/4885MAPK14 1293/4885 |
| US-20260125650-A1 | METHODS AND COMPOSITIONS FOR GENERATING HEPATOCYTES | WNT3A, GSK3B, GSK3A | TGFBR1 91/4885MTOR 173/4885MAPK14 162/4885 |
| US-20040220230-A1 | Pyridinylimidazoles | NR0B1, NR1I2, NR0B2 | TGFBR1 485/4885MTOR 4099/4885MAPK14 3471/4885 |
| US-12590297-B2 | Differentiation method | WNT3A, SFRP1, WNT1 | TGFBR1 45/4885MTOR 264/4885MAPK14 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.